Professor Ann-Lii Cheng

 
Specialty:
  1. Internal Medicine
  2. Hematology
  3. Oncology
 
Current Position:
  • Distinguished Professor, Department of Internal Medicine, National Taiwan University College of Medicine
  • Director, Graduate Institute of Oncology, National Taiwan University College of Medicine
  • Director, Department of Medical Oncology, National Taiwan University Hospital
 
Education:
  • M.D., Department of Medicine, National Taiwan University College of Medicine
  • Ph.D., Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine
  • Research Fellow, Graduate Institute of Biomedical Sciences, Academia Sinica
  • Research Fellow, Clinical Cancer Center, University of Wisconsin
 
Tel: 886-2-23123456 #67011
Fax: 886-2-23711174
E-mail: alcheng@ntu.edu.tw
Website: http://oncology.ntu.edu.tw/people/bio.php?PID=3
 
Introduction:
    Professor Ann-Lii Cheng is currently Director of Department of Oncology, NTUH and Director of Graduate Institute of Oncology, NTUCM. The research group of Prof. Chen has published over 200 SCI papers including high impact journals, such as the Journal of Clinical Oncology, Lancet Oncology, the Journal of the National Cancer Institute, Blood and Hepatology. Prof. Chen received Outstanding Academic Research Awards recognized by NSC, Outstanding Academic Research Award recognized by Executive Yuan in 2008 and Academic Awards of Ministry of Education in 2010 and is one of the few distinguished basic and clinical researchers.
 
Selected Publications:
  1. Kuo YH, Lin CH, Shau WY, Chen TJ, Yang SH, Huang SM, Hsu C, Lu YS, Cheng AL. Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy. BMC Cancer. 2012; 12: 620.
  2. Lin CH, Liu JM, Lu YS, Lan C, Lee WC, Kuo KT, Wang CC, Chang DY, Huang CS, Cheng AL. Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation. J Clin Pathol. 2013; 66(2): 140-5.
  3. Wu PF, Huang WC, Yang JC, Lu YS, Shih JY, Wu SG, Lin CH*, Cheng AL. Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas. J Neurooncol. 2013; 115(1): 61-70.
  4. Chen WW, Chang DY, Huang SM, Lin CH, Hsu C, Lin MH, Huang CS, Lu YS, Cheng AL. The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines. Breast. 2013; doi:pii: S0960-9776
  5. Ho YF, Lu WC, Chen RR, Cheng AL, Yeh KH.  Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. Anticancer Drugs. 2011 Mar;22(3):290-8.
  6. Shao YY, Lu LC, Cheng AL, Hsu CH.: Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of anti-angiogenic targeted therapy.  The Oncologist  2011;16(1):82-6
  7. Rodriguez BA, Weng YI, Liu TM, Zuo T, Hsu PY, Lin CH, Cheng AL, Cui H, Yan PS, Huang TH.  Estrogen-Mediated Epigenetic Repression of the Imprinted Gene Cyclin Dependent Kinase Inhibitor 1C in Breast Cancer Cells. Carcinogenesis. 2011 Feb (in press).
  8. Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, Chen PJ, Cheng AL*. Activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2011 Jan 4. (in press)
  9. Chiang CT, Yeh PY, Gao M, Chen CW, Yeh LC, Feng WC, Kuo SH, Hsu CH, Lu YS, Cheng AL. Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma. Cancer Lett. 2010 Dec 8;298(2):195-203.
  10. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL*. CIP2A mediates effects of bortezomib on phosphor-Akt and apoptosis in hepatocellular carcinoma cells.  Oncogene 2010 Nov 25;29(47):6257-66.
  11. Liu TY, Chen SU, Kuo SH, Cheng AL, Lin CW. E2A-positive gastric MALT lymphoma has weaker plasmacytoid infiltrates and stronger expression of the memory B-cell-associated miR-223: possible correlation with stage and treatment response. Mod Pathol. 2010 Nov;23(11):1507-17
  12. Ou DL, Shen YC, Yu SL, Chen KF, Yeh PY, Fan HH, Feng WC, Wang CT, Lin LI, Hsu C, Cheng AL*. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2010 Nov 15;70(22):9309-18.
  13. Chen KF, Tai WT, Liu TH, Huang HP, Lin YC, Shiau CW, Li PK, Chen PJ, Cheng AL*. Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3. Clin Cancer Res. 2010 Nov 1;16(21):5189-99.
  14. Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010 Oct 1;116(19):4590-6
  15. Weng YI, Hsu PY, Liyanarachchi S, Liu J, Deatherage DE, Huang YW, Zuo T, Rodriguez B, Lin CH, Cheng AL, Huang TH.  Epigenetic influences of low-dose bisphenol A in primary human breast epithelial cells. Toxicol Appl Pharmacol. 2010 Oct 15;248(2):111-21
  16. Kudo M, Han KH, Kokudo N, Cheng AL, Choi BI, Furuse J, Izumi N, Park JW, Poon RT, Sakamoto M. Liver Cancer Working Group report. Jpn J Clin Oncol. 2010 Sep;40 Suppl 1:i19-27.
  17. Wu PC, Huang LM, Kao CL, Fan TY, Cheng AL, Chang LY. An outbreak of coxsackievirus A16 infection: comparison with other enteroviruses in a preschool in Taipei. J Microbiol Immunol Infect. 2010 Aug;43(4):271-7.
  18. Lin ZZ, Jeng YM, Hu FC, Pan HW, Tsao HW, Lai PL, Lee PH, Cheng AL, Hsu HC. Significance of Aurora B overexpression in hepatocellular carcinoma. BMC Cancer. 2010 Aug 28;10(1):461.
  19. Shen YC, Hsu C, Cheng AL*. Molecular targeted thearpy for advanced hepatocellular carcinoma: current status and future perspectives.  J Gastroenterol. 2010 Aug;45(8):794-807.
  20. Lin WC, Tsai HF, Kuo SH, Wu MS, Lin CW, Hsu PI, Cheng AL, Hsu PN. Translocation of Helicobacter pylori CagA into Human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphoma. Cancer Res. 2010 Jul 15;70(14):5740-8.
  21. Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, Cheng AL*. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol. 2010 Jul;53(1):126-31.
  22. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL*. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol. 2010 Jun;52(6):889-94.
  23. Shao YY, Hu FC, Liang JT, Chiu WT, Cheng AL, Yang CH. Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions. J Formos Med Assoc. 2010 May;109(5):362-8.
  24. Lin PH, Lu YS, Lin CH, Chang DY, Huang CS, Cheng AL, Yeh KH.  Vinorelbine plus 24-Hour Infusion of High-dose 5-Fluorouracil and Leucovorin as Effective Palliative Chemotherapy for Breast Cancer Patients with Acute Disseminated Intravascular Coagulation.  Anticancer Res. 2010;30(7):3087-91.
  25. Masao Omata, Laurentius A. Lesmana, Ryosuke Tateishi, Pei-Jer Chen, Shi-Ming Lin • Haruhiko Yoshida, Masatoshi Kudo, Jeong Min Lee, Byung Ihn Choi, Ronnie T. P. Poon, Shuichiro Shiina, Ann Lii Cheng, Ji-Dong Jia, Shuntaro Obi, Kwang Hyub Han, Wasim Jafri, Pierce Chow, Seng Gee Lim, Yogesh K. Chawla, Unggul Budihusodo, Rino A. Gani, C. Rinaldi Lesmana, Terawan Agus Putranto, Yun Fan Liaw, Shiv Kumar Sarin. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int  2010;4:439–474
  26. Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, Hsu C, Kuo WH, Chang KJ, Lin CH, Cheng AL.  Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin.  Jpn J Clin Oncol. 2010 Apr;40(4):286-93.
  27. Kuo SH, Yen RF, Lin CW, Chen LT, Tien HF, Cheng AL*. Unusual presentation of multiple pathologic bone fractures in a patient with gastric mucosa-associated lymphoid tissue lymphoma.  Ann Hematol 2010 Apr;89(4):431-6.
  28. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010 Mar 18;4(2):439-74.
  29. Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, Lin ZZ, Chao TY, Cheng AL*. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.  Br J Cancer. 2010 Mar 16;102(6):981-6
  30. Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL*.  Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol. 2010;52:88-95.
  31. Yan KH, Yao CJ, Chang HY, Lai GM, Cheng AL, Chuang SE. The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. Mol Carcinog. 2010 Mar;49(3):235-46.
  32. Hsu C, Shen YC, Cheng CC, Hu FC, Cheng AL*.  Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design.  Contemp Clin Trials 2010 Jan;31(1):55-61.
  33. Lin CH, Lien HC, Hu FC, Lu YS, Kuo SH, Wu LC, You SL, Cheng AL, Chang KJ, Huang CS. Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. J Zhejiang Univ Sci B. 2010 Jan;11(1):1-9.
  34. Wu PF, Kuo KT, Kuo LT, Lin YT, Lee WC, Lu YS, Yang CH, Wu RM, Tu YK, Tasi JC, Tseng HM, Tseng SH, Cheng AL, Lin CH.  O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.  Lung Cancer 2010 Jun;68(3):484-90.
  35. Masatoshi Kudo, Kwang Hyub Han, Norihiro Kokudo, Ann-Lii Cheng, Byung Ihn Choi, Junji Furuse, Namiki Izumi, Joong-Won Park, Ronnie T. Poon, and Michiie Sakamoto.  Liver Cancer Working Group Report .  Jpn. J. Clin. Oncol. (2010) 40(suppl 1): i19-i27
  36. Chen JS, Chao Y, Hsieh RK, Cheng AL, Chen PM, Chiou TJ, Chao TY, Yeh KH, Chen LT, Whang-Peng J. A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan. Cancer Chemother Pharmacol. 2010 (in press).
  37. Ch'ang HJ, Huang CL, Wang HP, Shiah HS, Chang MC, Jan CM, Chen JS, Tien YW, Hwang TL, Lin JT, Cheng AL, Whang-Peng J, Chen LT.  Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer. Cancer Chemother Pharmacol. (in press).
  38. Hung CC, Chen PJ, Jeng YM, Cheng AL, Huang LR, Chia-Hsien Cheng J. Synergistic Effect of Radiation and Interleukin-6 on Hepatitis B Virus Reactivation in Liver through STAT3 Signaling Pathway.  Int J Radiat Oncol Biol Phys. (in press).
  39. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, Harmon C, Ruiz-Garcia A, Lechuga MJ, Cheng AL. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.  Lancet Oncol. 2009 Aug;10(8):794-800.
  40. Hsu C, Wei SC, Cheng AL, Chen PJ.  Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy. Hepatology. 2009 Aug;50(2):654-5.
  41. Lin CC, Hsu CH, Cheng JC, Huang CY, Tsai YC, Hsu FM, Huang KH, Cheng AL, Pu YS. Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer.  Int J Radiat Oncol Biol Phys. 2009;75(2):442-448.
  42. Ou DL, Shen YC, Yu SL, Lee WC, Yeh LC, Hsu C, Cheng AL*.  Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma. Clin Cancer Res. 2009;15(19):5820-8.
  43. Yang SH, Lin ZZ, Kuo SH, Cheng AL*.  Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma.  Am J Hematol. 2009 Jul;84(7):457-9.
  44. Chen CH, Hu FC, Huang GT, Lee PH, Tsang YM, Cheng AL, Chen DS, Wang JD, Sheu JC.  Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients.  Eur J Cancer. 2009 Jun;45(9):1630-9.
  45. Lin YC, Tsai CH, Wu JS, Huang CS, Kuo SH, Lin CW, Cheng AL*.  Clinicopathologic features and treatment outcome of non-Hodgkin lymphoma of the breast--a review of 42 primary and secondary cases in Taiwanese patients.  Leuk Lymphoma. 2009 Jun;50(6):918-24.
  46. Shao YY, Lin ZZ, Liang PC, Tien YW, Cheng AL*.  Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment.  Anticancer Res. 2009 May;29(5):1665-7.
  47. Lin CH, Liau JY, Lu YS, Huang CS, Lee WC, Kuo KT, Shen YC, Kuo SH, Lan C, Liu JM, Kuo WH, Chang KJ, Cheng AL*.  Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia.  Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1807-14.
  48. Hsu C, Shen Y-C, Cheng AL*. Sorafenib for the treatment of hepatocellular carcinoma across geographic regions. Expert Rev. Clin. Pharmacol.  2009; 2(2):129-136.
  49. Lee JH, Cheng AL, Lin CW, Kuo SH. Multifocal primary cutaneous CD30+ anaplastic large cell lymphoma responsive to thalidomide: the molecular mechanism and the clinical application. Br J Dermatol. 2009 Apr;160(4):887-9.
  50. Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, Chen PJ, Cheng AL*.  Bortezomib overcomes TRAIL resistance in hepatocellular carcinoma cells in part through the inhibition of PI3K/Akt pathway. J Biol Chem. 2009 Apr 24;284(17):11121-33.
  51. Shen YC, Hu FC, Jeng YM, Chang YT, Lin ZZ, Chang MC, Hsu C, Cheng AL*. Nuclear Over-expressions of Mitotic Regulatory Proteins in Biliary Tract Carcinoma: Correlation with Clinico-Pathological Features and Patient Survival.  Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):417-23.
  52. Huang CL, Yang CH, Yeh KH, Hu FC, Chen KY, Shih JY, Lin ZZ, Yu CJ, Cheng AL, Yang PC.  EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer. 2009 Jun;64(3):346-51.
  53. Lin ZZ, Hsu HC, Hsu CH, Yeh PY, Huang CYF, Huang YF, Chen TJ, Kuo SH, Hsu C, Hu FC, Jeng YM, Chung Y, and Cheng AL*.  The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma.  J Hepatol. 2009 Mar;50(3):518-27.
  54. Cheng AL*, Kang YK, Chen ZD, Tsao CJ, Qin SK, Kim JS, Luo RC, Feng JF, Ye SG, Yang TS, Su JM, Sun Y, Liang HJ, Liu JW, Wang JJ, Tak WY, Pan HM, Burock K, Zou J, Voliotis D, Guen ZZ.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: results of a phase III randomized, double-blind, placebo-controlled trial conducted in the Asia-Pacific region.  Lancet Oncol 2009 Jan;10(1):25-34.
  55. Lin CC, Pu YS, Hsu CH, Keng HY, Cheng AL and Yang CH*. Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations Urol Oncol. 2008 ;26(6):659-61.
  56. Lin HJ, Zuo T, Lin CH, Kuo CT, Liyanarachchi S, Sun S, Shen R, Deatherage DE, Potter D, Asamoto L, Lin S, Yan PS, Cheng AL, Ostrowski MC, Huang TH.  Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells. Cancer Res. 2008 Dec 15;68(24):10257-66.
  57. Kuo SH, Huang CS, Kuo WH, Cheng AL, Chang KJ, Cheng JC. Comprehensive locoregional treatment and systemic therapy for postmastectomy isolated locoregional recurrence. Int J Radiat Oncol Biol Phys 2008, Dec 1;72(5):1456-1464.
  58. Lin YC, Wei LH, Shun CT, Cheng AL, Hsu CH. Disseminated Peritoneal Leiomyomatosis Responds to Systemic Chemotherapy. Oncology. 2008 Nov 27;76(1):55-58.
  59. Gao M, Yeh PY, Lu YS, Hsu CH, Chen KF, Lee WC, Feng WC, Chen CS, Kuo ML and Cheng AL*. OSU-03012, a Novel Celecoxib Derivative, Induces Reactive Oxygen Species-related Autophagy in Hepatocellular Carcinoma. Cancer Res. 2008 Nov 15;68(22):9348-57.
  60. Gao M, Yeh PY, Lu YS, Chang WC, Kuo ML, Cheng AL*.  NF-kappaB p50 promotes tumor cell invasion through negative regulation of invasion suppressor gene CRMP-1 in human lung adenocarcinoma cells. Biochem Biophys Res Commun. 2008;376:283-287.
  61. Kuo SH, Yeh PY, Chen LT, Wu MS, Lin CW, Yeh KH, Tzeng YS, Chen JY, Hsu PN, Lin JT, Cheng AL*. Overexpression of B-cell activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma.  Blood. 2008 Oct 1;112(7):2927-34.
  62. Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun CT, Huang CL, Bean J, Cheng AL, Pao W, Yang PC.  Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.  J Clin Oncol. 2008 Jun 1;26(16):2745-53.
  63. Kuen-Feng Chen, Pei-Yen Yeh, Kun-Huei Yeh, Yen-Shen Lu, Shang-Yi Huang, Ann-Lii Cheng*. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Research 2008;68(16):6698-707.
  64. Lin ZZ, Hsu C, Chang YC, Yu CJ, Hsu CH, Lin CC, Cheng AL, Yang PC, Yang CH. Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment. Lung Cancer. 2008 May;60(2):215-21.
  65. Huang TC, Yeh KH, Cheng AL, Hsu CH. Weekly 24-hour infusional 5-fluorouracil as initial treatment for advanced gastric cancer with acute disseminated intravascular coagulation. Anticancer Res. 2008 Mar-Apr;28(2B):1293-7
  66. Jui-Hsiang Hung, Yen-Shen Lu, Yu-Chieh Wang, Yi-Hui Ma, Da-Sheng Wang, Samuel K. Kulp, Natarajan Muthusamy, John C. Byrd, Cheng AL and Ching-Shih Chen. FTY720 Induces Apoptosis in Hepatocellular Carcinoma Cells through Activation of Protein Kinase C  Signaling.  Cancer Res. 2008 Feb 15;68(4):1204-12.
  67. Lien HC, Lu YS, Shun CT, Yao YT, Chang WC, Cheng AL*.  Differential expression of glucocorticoid receptor in carcinomas of the human digestive system.  Histopathology. 2008 Feb;52(3):314-24.
  68. Kuo SH, Chen LT, Wu MS, Lin CW, Yeh KH, Kuo KT, Yeh PY, Tzeng YS, Wang HP, Hsu PN, Lin JT, Cheng AL*. Long-term Follow-up of Gastrectomized Patients With Mucosa-associated Lymphoid Tissue Lymphoma: Need for a Revisit of Surgical Treatment. Ann Surg. 2008 Feb;247(2):265-269.
  69. Hsu C, Chao AH, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheng AL*, Chen PJ.  A revisit for prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-hodgkin’s lymphoma: a randomized trial.  Hepatology  2008;47:844-853
  70. Hsu C, Kuo SH, Hu FC, Cheng AL, Shih JY, Yu CJ, Lin CC, Huang TC, Yang PC, Yang CH*. Gemcitabine plus Conventional-dose Epirubicin versus Gemcitabine plus Cisplatin as First-line Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Carcinoma-A randomized phase II trial Lung Cancer 2008;62,334-343
  71. Chen YM, Yu CJ, Yang CH, Perng RP, Tsia Cm, Shih JF, Cheng AL, Lefresene F, Barbier M Pouget JC and Yang PC. A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma. Lung Cancer 2007;56:89-95
  72. Lin YL, Chung CY, Chang CS, Wu JS, Kuo KT, Kuo SH, Cheng AL*. Prognostic Factors in Extrapulmonary Small Cell Carcinomas. A Large Retrospective Study.  Oncology. 2007 Dec 20;72(3-4):181-187.
  73. Shen YC, Hsu C, Cheng AL*. Molecular Targeted therapy for advanced hepatocellular carcinoma.  Targeted Oncology 2007;2:199-210.
  74. Huang SY, Yao M, Tang JL, Lee WC, Tsay W, Cheng AL, Wang CH, Chen YC, Shen MC, Tien HF. Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years. Cancer. 2007 Aug 15;110(4):896-905.
  75. Lin CC, Yeh KH, Yang CH, Hsu C, Tsai YC, Hsu WL, Cheng AL, Hsu CH.  Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.  Anticancer Drugs. 2007 Jul;18(6):703-8.
  76. Hsu CH, Cheng AL.  Clinical studies with curcumin.  Adv Exp Med Biol. 2007;595:471-80. (Review)
  77. Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, Tang M, Lin ZZ, Chen TJ, Cheng AL, Chen CS.  Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology. 2007 Jul 25;46(4):1119-1130
  78. Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, Chuang SE. Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL.  Cancer Res. 2007 Apr 15;67(8):3878-87.
  79. Lin CC, Hsu CH, Huang CY, Keng HY, Tsai YC, Huang KH, Cheng AL, Pu YS.  Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study. Anticancer Drugs. 2007 Apr;18(4):487-91.
  80. Lin CC, Hsu CH, Huang CY, Tsai YC, Huang KH, Cheng AL, Pu YS. Prognostic factors for metastatic urothelial carcinoma treated with Cisplatin and 5-Fluorouracil-based regimens. Urology. 2007 Mar;69(3):479-84.
  81. Chou CH, Chen PJ, Lee PH, Cheng AL, Hsu HC, Cheng JC. Radiation-induced hepatitis B virus reactivation in liver mediated by the bystander effect from irradiated endothelial cells. Clin Cancer Res. 2007 Feb 1;13(3):851-7.
  82. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial.  Invest New Drugs. 2007 Feb;25(1):77-84 .
  83. Lin CC, Cheng AL, Hsu CH, Lu YS, Hsu C, Yeh KH, Wu CY, Huang CS, Yang CH. A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer.  Anticancer Res. 2007 Jan-Feb;27(1B):641-5.
  84. Lin CC, Hsu CH, Huang CY, Cheng AL, Vogelzang NJ, Pu YS. Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma. J Urol. 2007 Jan;177(1):84-9.
  85. Lin CC, Hsu CH, Hour TC, Cheng AL, Huang CY, Huang KH, Chen J, Pu YS. Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial.  Urol Oncol. 2007;25(3):207-13.
  86. Lin CC, Hsu CH, Cheng JC, Wang HP, Lee JM, Yeh KH, Yang CH, Lin JT, Cheng AL*, Lee YC.  Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol. 2007;18:93-98.
  87. Kuo SH, Chen LT, Wu MS, Kuo KT, Yeh KH, Doong SL, Mao TL, Yeh PY, Hsu HC, Tzeng YS, Lin CW, Lin JT, Cheng AL*: Differential response to Helicobacter pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALToma of stomach - significance of tumor cell clonality and BCL10 expression.  J Pathol. 2007;211:296-304.